Roles
- Associate Professor of Clinical Medicine
-
Biography
Terrence Bradley, M.D., is an Assistant Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine. He is a junior clinical investigator and an active member of the Phase 1 and Cancer Epigenetics Programs at Sylvester Comprehensive Cancer Center (SCCC). Dr. Bradley’s career goal is to become a leading clinical investigator in myeloid neoplasms, and his research focuses on advancing therapies for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs)—diseases associated with significant morbidity and mortality, for which novel therapies are urgently needed. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Research Interests
My clinical research interests are in novel therapies for AML, MDS, MPN, and ALL, largely through phase I/II clinical research. I also have a particular interest in LSD1 inhibition in these malignancies, and am PI on multiple investigator-initiated trials. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Sylvester Hosts Third Biennial Miami Leukemia Symposium
Sylvester K12 Symposium Brings Together Prior and New Award Winners
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 14 clinical trials.
-
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Investigator-Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
- Principal Investigator: Terrence Bradley
- Study Phase: Phase 3
- Enrollment Status: Closed
-
To compare SVR35 between Arm 1 and Arm 2To compare TSS50 between Arm 1 and Arm 2
- Principal Investigator: Terrence Bradley
- Study Phase: Phase III
- Enrollment Status: Open
-
To evaluate the safety, tolerability, and DLTs anddetermine the MTD and/or RDE(s) of INCA033989 inparticipants with MF or ET.To evaluate the preliminary activity of INCA033989 inparticipants with MF.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this research is to gather information on the safety and effectiveness of ruxolitinib in combination with ivosidenib. Both of the drugs used in this study have been approved by the US Food and Drug Administration (FDA) but not for the use on study. Ruxolitinib is FDA approved to treat various types of blood diseases and to treat serious side effects of bone marrow transplants, however it is not approved to treat cancer. Ivosidenib is FDA approved to treat blood cancers that are IDH1-mutated, however it is not approved to be given in combination with ruxolitinib. For these reasons, the combination of ivosidenib and ruxolitinib as given in this study is experimental.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I
- Enrollment Status: Open
-
Primary objective: to assess safety and determine the maximum tolerated dose of EP31670 in patients with targeted advanced solid tumors (Part 1) or targeted advanced hematological malignancies (Part 2) or in combination with ruxolitinib or momelotinib in patients with myelofibrosis who have not achieved an adequate response or have lost response to a JAK inhibitor-containing regimen (Part 3).Secondary objectives: to evaluate the pharmacokinetic and pharmacodynamic effects of EP31670; to assess anti-tumor activity.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I
- Enrollment Status: Open
-
An Open Label, Phase 1/1b Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Clinical Activityof Imetelstat in Combination with Ruxolitinib in Patientswith Myelofibrosis.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I
- Enrollment Status: Open
-
The primary purpose of this study is to evaluate the safety of TP-3654 at different doses to find out what effects, if any, it has on people. This study will also gain information about the pharmacokinetics (PK) (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body) and pharmacodynamic (PD) biomarkers (which are used to examine the drug effect on the body and/or the tumor) for TP-3654.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I/II
- Enrollment Status: Open
-
To determine the safety profile, and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of bomedemstat when combined with venetoclax administered orally in patients with relapsed or refractory AML.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this study is to compare the usual treatment (ASTX727) alone to using iadademstat plus the usual treatment. Two proteins involved in regulating gene function, lysine-specific demethylase 1 (LSD1) and DNA methyltransferase 1 (DNMT1), are known to play roles in the development of MPN in people. ASTX727 and iadademstat are drugs that make DMNT1 and LSD1 less effective in the body. The addition of iadademstat to ASTX727 could shrink your cancer. But it could also cause side effects, which are described in the risks section below.
- Principal Investigator: Terrence Bradley
- Study Phase: Phase II
- Enrollment Status: Open